Xalud Therapeutics Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $30M
Latest Deal Amount
  • Investors
  • 3

Xalud Therapeutics General Information

Description

Developer of a gene therapy platform designed to treat neuroinflammatory diseases. The company's platform creates therapies that use new strategies in pain management that target neuropathic pain effectively and getting to the root of the disease, enabling doctors to help patients get relief from inflammatory joint disorders including osteoarthritis and rheumatoid arthritis.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • 40 West 57th Street
  • Suite 1810
  • New York, NY 10019
  • United States
+1 (212) 000-0000

Xalud Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xalud Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 24-Aug-2021 $30M 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series B) 30-Mar-2020 000 000.00 0000 Completed Generating Revenue
2. Later Stage VC (Series A) 25-Jun-2015 $7.3M $7.3M 000.00 Completed Generating Revenue
1. Grant 31-Jan-2015 $4.23M Completed Generating Revenue
To view Xalud Therapeutics’s complete valuation and funding history, request access »

Xalud Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.0 00.0 00 00.0 000
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 36,838,389 $0.000100 $0.54 $0.54 1x $0.54 41.19%
To view Xalud Therapeutics’s complete cap table history, request access »

Xalud Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a gene therapy platform designed to treat neuroinflammatory diseases. The company's platform creates therap
Drug Discovery
New York, NY
13 As of 2021
000.00
0000 0000-00-00
00000000000 000.00

0000 000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000 0

, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis n
0000 000000000
Cambridge, MA
0 As of 0000
0000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xalud Therapeutics Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vera Therapeutics Venture Capital-Backed South San Francisco, CA 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed Cambridge, MA 0 0000 000000&0
00 000000000 Venture Capital-Backed Burnaby, Canada 00 000.00 0000000000 000.00
You’re viewing 3 of 3 competitors. Get the full list »

Xalud Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
Diem Nguyen Ph.D Chief Executive Officer, President & Board Member
Brendan O'Leary Chief Operating Officer
Steve Vicik Chief Technology Officer
Howard Rutman Chief Development Officer
Kristin Murray Chief Regulatory Officer
You’re viewing 5 of 13 executive team members. Get the full list »

Xalud Therapeutics Board Members (8)

Name Representing Role Since
Diem Nguyen Ph.D Xalud Therapeutics Chief Executive Officer, President & Board Member 000 0000
Jayson Rieger Ph.D PBM Capital Group Board Member 000 0000
Paul Manning Self Board Member 000 0000
Sean Stalfort PBM Capital Group Board Member 000 0000
Stephen Collins Ph.D Xalud Therapeutics Chief Medical Officer & Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Xalud Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xalud Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
PBM Capital Group PE/Buyout Minority 000 0000 000000 0
National institutes of Neurological Disorders and Stroke Other 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Xalud Therapeutics’s complete investors history, request access »